Deutsch English Français

Contact

EP1951304

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1951304

EP1951304 - METHOD FOR TREATING JOINT DAMAGE [Right-click to bookmark this link]
Status	Patent revoked Status updated on 10.12.2021 Database last updated on 28.03.2025
Former	The patent has been granted Status updated on 15.11.2018
Most recent event Tooltip	08.03.2024	Petition for review: decision	published on 10.04.2024 [2024/15]
Applicant(s)	For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4002 Basel / CH
	For all designated states Biogen Idec Inc. 14 Cambridge Center Cambridge, MA 02142 / US
	For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US
	[N/P]
Former [2008/38]	For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4002 Basel / CH
	For all designated states Biogen Idec Inc. 14 Cambridge Center Cambridge, MA 02142 / US
	For all designated states Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990 / US
Former [2008/32]	For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4002 Basel / CH
	For all designated states Biogen Idec Inc. 14 Cambridge Center Cambridge, MA 02142 / US
	For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 / US
Inventor(s)	01 / TOTORITIS, Mark 15797 Caminito Cantaras Del Mar, CA 92014 / US
	02 / SHAW, Timothy Mark 3 Brackenhill Berkhamsted Hertfordshire / GB
	03 / AGARWAL, Sunil 4 Wildflower Court Corte Madera, CA 94925 / US
	04 / YOCUM, David 1149 Shoreline Drive San Mateo, CA 94404 / US
	05 / KELMAN, Ariella 1732 Jackson Street, 204 South San Francisco, CA 94109 / US
	[2014/43]
Former [2008/32]	01 / TOTORITIS, Mark 15797 Caminito Cantaras Del Mar, CA 92014 / US
	02 / SHAW, Timothy Mark 3 Brackenhill Berkhamsted Hertfordshire / GB
	03 / AGARWAL, Sunil 4 Wildflower Court Corte Madera, CA 94925 / US
	04 / YOCUM, David 1149 Shoreline Drive San Mateo, CA 94404 / US
	05 / KELMAN, Ariella 1732 Jackson Street, 204 South San Francisco, CA 94109 / US
Representative(s)	Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
	[N/P]
Former [2014/43]	Walton, Seán Malcolm, et al Mewburn Ellis LLP 33 Gutter Lane London EC2V 8AS / GB
Former [2008/32]	Walton, Seán Malcolm, et al Mewburn Ellis LLP York House 23 Kingsway London WC2B 6HP / GB
Application number, filing date	06837634.2	14.11.2006
	[2008/32]
	WO2006US44290
Priority number, date	US20050737291P	15.11.2005 Original published format: US 737291 P
	US20060864463P	06.11.2006 Original published format: US 864463 P
	[2008/32]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2007059188
	Date:	24.05.2007
	Language:	EN
	[2007/21]
	Type:	A1 Application with search report
	No.:	EP1951304
	Date:	06.08.2008
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 24.05.2007 takes the place of the publication of the European patent application.
	[2008/32]
	Type:	B1 Patent specification
	No.:	EP1951304
	Date:	22.10.2014
	Language:	EN
	[2014/43]
Search report(s)	International search report - published on:	EP	24.05.2007
Classification	IPC:	A61K39/395, A61P19/02, A61K31/00, C07K16/28	[2008/32]
	CPC:	C07K16/2896 (EP,US); A61K39/395 (KR); C07K16/2887 (US); A61K31/519 (US); A61K39/3955 (US); A61K45/06 (US); (+) A61K47/6849 (EP,US); A61K9/0053 (KR); A61K9/20 (KR); A61P1/04 (EP); A61P17/06 (EP); A61P19/00 (EP); A61P19/02 (EP); A61P29/00 (EP); A61P37/00 (EP); A61P37/06 (EP); A61P43/00 (EP); C07K16/28 (KR); A61K2039/505 (EP,US); C07K2317/24 (EP,US); C07K2317/56 (EP,US); C07K2317/565 (EP,US); C07K2317/76 (US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/32]
Extension states	AL	03.06.2008
	BA	03.06.2008
	HR	03.06.2008
	MK	03.06.2008
	RS	03.06.2008
Title	German:	VERFAHREN ZUR BEHANDLUNG VON GELENKSCHÄDEN	[2008/32]
	English:	METHOD FOR TREATING JOINT DAMAGE	[2008/32]
	French:	PROCEDE DESTINE A TRAITER UNE LESION ARTICULAIRE	[2008/32]
Entry into regional phase	03.06.2008	National basic fee paid
	03.06.2008	Designation fee(s) paid
	03.06.2008	Examination fee paid
Examination procedure	04.06.2008	Amendment by applicant (claims and/or description)
	04.06.2008	Examination requested [2008/32]
	13.01.2009	Despatch of a communication from the examining division (Time limit: M06)
	10.11.2009	Reply to a communication from the examining division
	04.06.2010	Despatch of a communication from the examining division (Time limit: M06)
	17.02.2011	Reply to a communication from the examining division
	19.07.2011	Despatch of a communication from the examining division (Time limit: M04)
	28.10.2011	Reply to a communication from the examining division
	19.07.2012	Observations by third parties
	20.08.2012	Despatch of a communication from the examining division (Time limit: M02)
	29.10.2012	Reply to a communication from the examining division
	18.12.2012	Observations by third parties
	31.05.2013	Observations by third parties
	15.07.2013	Despatch of a communication from the examining division (Time limit: M06)
	21.02.2014	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	01.05.2014	Reply to a communication from the examining division
	15.07.2014	Observations by third parties
	29.07.2014	Communication of intention to grant the patent
	31.07.2014	Fee for grant paid
	31.07.2014	Fee for publishing/printing paid
	31.07.2014	Receipt of the translation of the claim(s)
Divisional application(s)	EP13178006.6 Application deemed to be withdrawn : 27.08.2013
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 13.01.2009
Opposition(s)	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Terre Bonne Business Park Building Z0 Route de Crassier 1 1262 Eysins / CH
		04 22.07.2015 06.11.2023 WITHDRAWN European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 19.03.2019 WITHDRAWN Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus Sendlinger Straße 29 80331 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT
		[N/P]
	Former [2023/51]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Terre Bonne Business Park Building Z0 Route de Crassier 1 1262 Eysins / CH
		04 22.07.2015 06.11.2023 WITHDRAWN European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 19.03.2019 WITHDRAWN Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus Sendlinger Straße 29 80331 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT
	Former [2023/47]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Terre Bonne Business Park Building Z0 Route de Crassier 1 1262 Eysins / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 19.03.2019 WITHDRAWN Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus Sendlinger Straße 29 80331 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	Former [2020/47]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Terre Bonne Business Park Building Z0 Route de Crassier 1 1262 Eysins / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 19.03.2019 WITHDRAWN Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus Brienner Straße 1 80333 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	Former [2019/41]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Terre Bonne Business Park Building Z0 Route de Crassier 1 1262 Eysins / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 19.03.2019 WITHDRAWN Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus Brienner Straße 1 80333 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Briscoe, Paul Brian, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	Former [2019/17]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Terre Bonne Business Park A2 Route de Crassier 15 1162 Eysins / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 19.03.2019 WITHDRAWN Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Brienner Strasse 1 80333 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Briscoe, Paul Brian, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	Former [2018/25]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Terre Bonne Business Park A2 Route de Crassier 15 1162 Eysins / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 21.08.2015 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Brienner Strasse 1 80333 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Briscoe, Paul Brian, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	Former [2017/48]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 21.08.2015 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Brienner Strasse 1 80333 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		09 10.04.2017 18.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Briscoe, Paul Brian, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	Former [2017/47]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		05 22.07.2015 21.08.2015 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Brienner Strasse 1 80333 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
		09 10.04.2017 18.04.2017 INTERVENTION Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Briscoe, Paul Brian, et al, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	Former [2017/30]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		05 22.07.2015 21.08.2015 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Erika-Mann Strasse 23 80636 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 INTERVENTION ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		09 10.04.2017 18.04.2017 INTERVENTION Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Briscoe, Paul Brian, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
	Former [2017/20]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		05 22.07.2015 21.08.2015 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Erika-Mann Strasse 23 80636 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 07.04.2017 12.04.2017 ADMISSIBLE Mundipharma GmbH Mundipharma Strasse 2 65549 Limburg / DE Opponent's representative Cornish, Kristina Victoria Joy, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		09 10.04.2017 INTERVENTION ADMISSIBLE Mundipharma Pharmaceutical s.r.l Via Serbelloni, n. 4 Milan / IT Opponent's representative Briscoe, Paul Brian, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
	Former [2015/47]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Limited 20 Red Lion Street London WC1R 4PJ / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		05 22.07.2015 21.08.2015 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Erika-Mann Strasse 23 80636 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	Former [2015/41]
	Opponent(s)	01 21.07.2015 21.08.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 21.08.2015 ADMISSIBLE Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 21.08.2015 ADMISSIBLE Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 21.08.2015 ADMISSIBLE European Oppositions Ltd 12 New Fetter Lane London EC4A 1AG / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		05 22.07.2015 21.08.2015 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 21.08.2015 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Erika-Mann Strasse 23 80636 München / DE
		07 22.07.2015 21.08.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	Former [2015/37]
	Opponent(s)	01 21.07.2015 ADMISSIBLE Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Binger Strasse 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 European Oppositions Ltd 12 New Fetter Lane London EC4A 1AG / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		05 22.07.2015 WITHDRAWN Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Erika-Mann Strasse 23 80636 München / DE
		07 22.07.2015 ADMISSIBLE Celltrion, Inc. 23 Academy-ro Yeonsu-gu Incheon 406-840 / KR Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	Former [2015/36]
	Opponent(s)	01 21.07.2015 Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Binger Strasse 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 European Oppositions Ltd 12 New Fetter Lane London EC4A 1AG / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		05 22.07.2015 Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
		06 22.07.2015 Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Erika-Mann Strasse 23 80636 München / DE
	Former [2015/35]
	Opponent(s)	01 21.07.2015 Richter Gedeon Nyrt. Gyömröi út 19-21 1103 Budapest / HU Opponent's representative Neuefeind, Regina Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80335 München / DE
		02 21.07.2015 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Binger Strasse 173 55216 Ingelheim am Rhein / DE Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 21.07.2015 Merck Serono S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH Opponent's representative Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH
		04 22.07.2015 European Oppositions Ltd 12 New Fetter Lane London EC4A 1AG / GB Opponent's representative Care, Alison, et al, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
		05 22.07.2015 Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Royle, Matthew Charles James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB
	01.09.2015	Invitation to proprietor to file observations on the notice of opposition
	11.05.2016	Reply of patent proprietor to notice(s) of opposition
	22.06.2017	No. 09: Notification indicating deficiencies in the notice of opposition
	04.09.2017	No. 09: Reply to notification indicating deficiencies in the notice of opposition
	27.06.2018	Date of oral proceedings
	16.11.2018	Despatch of minutes of oral proceedings
	16.11.2018	Despatch of communication that the patent will be revoked
	01.10.2020	Legal effect of revocation of patent [2022/02]
Appeal following opposition	05.12.2018	Appeal received No. T2842/18
	26.03.2019	Statement of grounds filed
	01.10.2020	Result of appeal procedure: appeal of the proprietor was rejected
	19.03.2021	Despatch of the decision of the Board of Appeal
	01.10.2020	Date of oral proceedings
Petition(s) for review:	Petition for review received
		Number: R0007/21
		for appeal No. T2842/18-3304
		Petitioner: APPR
	24.11.2023	Decision: Rejection of petition for review.
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	17.02.2011	Request for further processing filed
	17.02.2011	Full payment received (date of receipt of payment) Request granted
	02.03.2011	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	01.05.2014	Request for further processing filed
	01.05.2014	Full payment received (date of receipt of payment) Request granted
	15.05.2014	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	10.11.2009	Request for further processing filed
	10.11.2009	Full payment received (date of receipt of payment) Request granted
	25.11.2009	Decision despatched
Fees paid	Renewal fee
	03.06.2008	Renewal fee patent year 03
	12.11.2009	Renewal fee patent year 04
	12.11.2010	Renewal fee patent year 05
	14.11.2011	Renewal fee patent year 06
	13.11.2012	Renewal fee patent year 07
	07.11.2013	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	IS	22.02.2015
	GB	19.02.2016
	[2016/23]
Former [2015/23]	IS	22.02.2015
Cited in	International search	[X]WO0067796 (GENENTECH INC [US], et al) [X] 1-61,65-98,101-112 * example 1 *;
		[X]WO0222212 (IDEC PHARMA CORP [US]) [X] 1-61,65-98,101-112 * example 1; claim 34 *;
		[X]WO2004056312 (GENENTECH INC [US], et al) [X] 1-61,65-98,101-112 * examples 3,6,16; sequences 21, 22 *;
		[X]US2004202658 (BENYUNES MARK C [US]) [X] 1-112 * example 1; claim 12 *;
		[X]WO2004091657 (GENENTECH INC [US], et al) [X] 1-112 * example 1; sequences 1-4 *;
		[X]WO2005060999 (GENENTECH INC [US], et al) [X] 1-112 * page 12, line 19 - page 14, column 1, line 14; claims 1-7 * * example 1 *;
		[X] - PROTHEREO A ET AL, "REMISSION OF INFLAMMATORY ARTHROPATHY IN ASSOCIATION WITH ANTI-CD20THERAPY FOR NON-HODGKIN'S LYMPHOMA", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, (199911), vol. 38, no. 11, ISSN 1462-0324, pages 1150 - 1152, XP000942661 [X] 1-61,65-98,101-112 * the whole document * DOI: http://dx.doi.org/10.1093/rheumatology/38.11.1150
		[X] - EDWARDS J C W ET AL, "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, (200102), vol. 40, no. 2, ISSN 1462-0324, pages 205 - 211, XP002348931 [X] 1-61,65-98,101-112 * page 206, column RIGHT, paragraph 2; tables 1,2 * * page 207, column LEFT, paragraphs 2-4 * DOI: http://dx.doi.org/10.1093/rheumatology/40.2.205
		[X] - KNEITZ C ET AL, "Improvement of refractory rheumatoid arthritis after depletion of B cells.", SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 2004, (2004), vol. 33, no. 2, ISSN 0300-9742, pages 82 - 86, XP008076371 [X] 1-61,65-98,101-112 * page 82, column RIGHT, paragraph LAST - page 83, column LEFT, line 1; table 1 * * page 83, column LEFT, paragraph 2 * * page 85, column RIGHT, paragraph LAST * DOI: http://dx.doi.org/10.1080/03009740310004379
		[X] - GENENTECH, "Phase III Study Shows Rituxan Significantly Improves Symptoms in Patients with Rheumatoid Arthritis Who Inadequately Responded to Anti-TNF Therapies", GENENTECH PRESS RELEASE, Internet, (20050405), pages 1 - 2, URL: http://www.gene.com/gene/news/press-releases/display.do?method=print&id=8267, (20070312), XP002425321 [X] 1-61,65-98,101-112 * the whole document *
		[X] - EDWARDS, "Efficacy and Safety of Rituximab, a B-Cell Targeted Chimeric Monoclonal Antibody: A Randomized, Placebo-Controlled Trial in Patients with Rheumatoid Arthritis", ARTHRITIS & RHEUMATISM, USA, vol. 46, no. 9suppl, (20021025), absract 446, URL: http://www.hopkins-arthritis.som.jhmi.edu/edu/acr2002/ra-treatments.html#rituximab, (20070309), XP002425322 [X] 1-61,65-98,101-112 * abstract *
		[X] - EMERY, "PRIMARY ANALYSIS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL OF RITUXIMAB, AN ANTI-CD20 MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING METHOTREXATE (DANCER TRIAL", ANNALS OF THE RHEUMATIC DISEASES, vol. 64, no. suppl3, (200506), pages 1 - 2, oral presentation, URL: http://eular.bmj.com/cgi/content/abstract/ardmtg;64/Suppl_3/182?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=emery&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=20&sortspec=relevance&volume=64&resourcetype=HWCIT,HWELTR, (2009), XP002425323 [X] 1-61,65-98,101-112 * the whole document * DOI: http://dx.doi.org/10.1136/ard.2004.025072
		[X] - LEANDRO M J ET AL, "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, (200210), vol. 61, no. 10, ISSN 0003-4967, pages 883 - 888, XP002348932 [X] 1-61,65-98,101-112 * page 884; tables 1,2 * DOI: http://dx.doi.org/10.1136/ard.61.10.883
		[X] - DE VITA SALVATORE ET AL, "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, (200208), vol. 46, no. 8, ISSN 0004-3591, pages 2029 - 2033, XP002306249 [X] 1-112 * page 2032, column LEFT, paragraph LAST; tables 1,2 *
		[X] - MOORE J ET AL, "A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation.", BONE MARROW TRANSPLANTATION AUG 2004, (200408), vol. 34, no. 3, ISSN 0268-3369, pages 241 - 247, XP002425324 [X] 1-61,65-98,101-112 * page 242, column LEFT, paragraph 2 * * page 245, column RIGHT, paragraph 2 - page 246, column LEFT, paragraph LAST * DOI: http://dx.doi.org/10.1038/sj.bmt.1704570
		[X] - GOTTENBERG J-E ET AL, "Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.", ANNALS OF THE RHEUMATIC DISEASES JUN 2005, (200506), vol. 64, no. 6, ISSN 0003-4967, pages 913 - 920, XP002425325 [X] 1-61,65-98,101-112 * page 916, column LEFT, paragraph 5; table 1 * DOI: http://dx.doi.org/10.1136/ard.2004.029694
		[X] - ANONYMOUS, "MabThera highly effective in treating rheumatoid arthritis", NEWS-MEDICAL.NET, (20050609), pages 1 - 2, URL: http://www.news-medical.net/print_article.asp?id=10840, (20070309), XP002425326 [X] 1-61,65-98,101-112 * the whole document *
		[X] - HIGASHIDA, "Safety and Efficacy of Rituximab in the Treatment of Refractory Rheumatoid Arthritis. Session Type: Poster Session 139-I", BLOOD, USA, (20031116), vol. 102, no. 11, page 1, XP002425327 [X] 1-61,65-98,101-112 * abstract * DOI: http://dx.doi.org/10.1182/blood-2003-05-1447
		[X] - ANONYMOUS, NCT00077870, "A Safety Study of Escalating Doses of PRO70769 for Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate", CLINICALTRIALS.GOV, internet, (20040212), pages 1 - 3, URL: http://clinicaltrials.gov/ct/show/NCT00077870;jsessionid=CDF4C4B9EF58B79A0FEED8ACAAB7AC4F?order=21, (20070319), XP002425328 [X] 1-61,65-98,101-112 * page 1, paragraph PURPOSE *
		[A] - EDWARDS J C W ET AL, "B LYMPHOCYTE DEPLETION THERAPY WITH RITUXIMAB IN RHEUMATOID ARTHRITIS", RHEUMATIC DISEASES CLINICS OF NORTH AMERICA, W.B. SAUNDERS, PHILADELPHIA, PA, US, (2004), vol. 30, no. 2, ISSN 0889-857X, pages 393 - 403, XP008076293 [A] 1-112 * page 398, paragraph 3 * * page 396, paragraph 4 - page 397, paragraph 4 * DOI: http://dx.doi.org/10.1016/j.rdc.2004.01.006
		[X] - GENENTECH, "Biogen Idec and Genentech Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for Rituxan in Rheumatoid Arthritis", INTERNET ARTICLE, USA, (20051031), pages 1 - 2, URL: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=9047, (20070309), XP002425329 [X] 1-61,65-98,101-112 * page 1, paragraphs 1-7 *
		[PX] - HIBBLE, "Rehaumatoid arthritis - MabThera provides lasting benefits", MEDICAL NEWS TODAY, (20051121), pages 1 - 2, URL: http://www.medicalnewstoday.com/medicalnews.php?newsid=33811, (20070309), XP002425335 [PX] 1-61,65-98,101-112 * the whole document *
		[A] - EDWARDS J C W ET AL, "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, (200208), vol. 30, no. 4, ISSN 0300-5127, pages 824 - 828, XP002306250 [A] * page 826, column RIGHT, paragraph 4 - page 827, paragraph 3; table 1 * DOI: http://dx.doi.org/10.1042/BST0300824
		[A] - FIELDS, "Rituximab in the treatment of rheumatoid arthritis, systemic lupus, and other autoimmune diseases: past, present, and future Special Report", HOSPITAL OF SPECIAL SURGERY, (20021025), pages 1 - 9, URL: http://www.hss.edu/professional-conditions_13466.asp?refName=Autoimmune+Diseases, (20070309), XP002425336
		[PX] - BATHON, "Rheumatoid arthritis treatments", THE JOHN HOPKINS ARTHRITIS CENTER, 2005 AMERICAN COLEGE OF RHEUMATOLOGY, USA, pages 1 - 12, URL: http://www.hopkins-arthritis.som.jhmi.edu/edu/acr2005/ra-treatments.html, (20070309), XP002425337 [PX] 1-112 * paragraphs [ABS.1830] , [1917] , [1922] *
	Examination	- MEASE PHILIP J ET AL, "Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.", THE JOURNAL OF RHEUMATOLOGY MAY 2010 LNKD- PUBMED:20194448, (201005), vol. 37, no. 5, ISSN 0315-162X, pages 917 - 927
		- EUROPEAN MEDICINES AGENCY, "Summary of product characteristics", (20091030), pages 1 - 91, European Medicines Agency, URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf
		- FDA, "Rituxan: prescribing information", USA, (1997), pages 1 - 38
		- PAVELKA K ET AL, "Efficacy and safety following repeated courses of rituximab in patients with active rheumatoid arthritis", ANNALS OF THE RHEUMATIC DISEASES, & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY; VIENNA, AUSTRIA; JUNE 08 -11, 2005, (200507), vol. 64, no. Suppl. 3, ISSN 0003-4967, page 435
		- FLEISCHMANN R M ET AL, "Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis.", ARTHRITIS & RHEUMATISM, & 69TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/40TH ANNUAL SCIENTIFIC MEETIN; SAN DIEGO, CA, USA; NOVEMBER 12 -17, 2005, (200509), vol. 52, no. 9, Suppl. S, ISSN 0004-3591, page S131
		- EMERY P ET AL, "Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis", ARTHRITIS & RHEUMATISM, & 69TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/40TH ANNUAL SCIENTIFIC MEETIN; SAN DIEGO, CA, USA; NOVEMBER 12 -17, 2005, (200509), vol. 52, no. 9, Suppl. S, ISSN 0004-3591, page S341
		- PINCUS T ET AL, "Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures.", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2004 SEP-OCT, (200409), vol. 22, no. 5 Suppl 35, ISSN 0392-856X, pages S50 - S56
	by applicant	US3773919
		US5500362
		US5736137
		WO9818921
		US5821337
		WO0040716
		WO0068378
		WO0112812
		US6528624
		WO03068822
		US6737056
		WO2004056312
		- ALAMONOSA; DROSOS, AUTOIMMUN. REV., (2005), vol. 4, pages 130 - 136
		- KEYSTONE, RHEUMATOLOGY, (2005), vol. 44, no. 2, pages II8 - IIL2
		- BUKHARI ET AL., ARTHRITIS RHEUM., (2002), vol. 46, pages 906 - 912
		- HELIOVAARA ET AL., ANN. RHEUM. DIS., (1995), vol. 54, pages 811 - 814
		- TEITELBAUM, SCIENCE, (2000), vol. 289, pages 1504 - 1508
		- GOLDRING; GRAVALLESE, ARTHRITIS RES., (2000), vol. 2, no. 1, pages 33 - 37
		- HOSSBAUER ET AL., J. BONE MINER. RES., (2000), vol. 15, no. 1, pages 2 - 12
		- FELDMANN ET AL., CELL, (1996), vol. 85, no. 3, pages 307 - 310
		- RAVETCH; KINET, ANNU. REV. IMMUNOL., (1991), vol. 9, pages 457 - 492
		- CLYNES ET AL., PNAS (USA), (1998), vol. 95, pages 652 - 656
		- J. BIOL. CHEM., (2004), vol. 279, no. 16, pages 16727 - 16735
		- STUVE ET AL., NEUROLOGY, (2002), vol. 8, pages 290 - 301
	other	WO2004091567
		- FLEISCHMANN ET AL, "Preliminary Efficacy results of Rituximab Retreatment in Patients with Active Rheumatoid Arthritis.", ARTHRITIS AND RHEUMATISM, (2005), vol. 52, no. SUPPL. 9 ABSTRACT #264, page S131, XP003032169
		- PAVELKA K. ET AL, "Efficacy and safety following repeated courses of rituximab in patients with active rheumatoid arthritis.", ANN RHEUM. DIS., (2005), vol. 64, no. SUP1, page 435, XP003032170
		- EMERY P. ET AL, "Safety and tolerability of Rituximab retreatment in patients with active rheumatoid arthritis.", ARTHRITIS AND RHEUMATISM, (2005), vol. 52, no. SUPPL. 9 #860, page S341, XP003032171
		- "PUBLICATION SCHEDULE 2005", ARTHRITIS AND RHEUMATISM, (2005), vol. 52, no. 9,SUP, XP003035144
		- "RITUXIMAB IN RA: DANCER STUDY CONFIRMS EFFICACY", MEDSCAPE, VIENA, AUSTRIA, (20050614), pages 1 - 5, URL: HTTP://WWW.MEDSCAPE.COM/VIEWARTICLE/538249, XP003035145
		- PINCUS T. ET AL, "RELATIVE VERSUS ABSOLUTE GOALS OF THERAPIES FOR RA:ACR 20 OR ACR 50 RESPONSES VERSUS TARGET VALUES FOR "NEAR REMISSION" OF DAS OR SINGLE MEASURES", CLIN EXP RHEUMATOL., (2004), vol. 22, no. 5 SUP.35, pages S50 - S56, XP003035146
	Opposition	- MEDSCAPE FLEISCHMANN et al., "Rituximab in RA: DANCER study confirms efficacy;", Preliminary Efficacy Results of Rituximab Retreatment in Patients with Active Rheumatoid Arthritis, (20050614), vol. 264;, page S 131;, XP003035145
		- EMERY et al., "Arthritis & Rheumatism,", Safety and Tolerability of Rituximab Retreatment in Patients with Active Rheumatoid Arthritis, (20050000), vol. 860;, page S341;, XP003032171
		- MEDSCAPE FLEISCHMANN et al., "Rituximab in RA: DANCER study confirms efficacy;", Preliminary Efficacy Results of Rituximab Retreatment in Patients with Active Rheumatoid Arthritis, (20050614), vol. 264, pages 1 - 5, XP003035145
		- EMERY et al., "Safety and Tolerability of Rituximab Retreatment in Patients with Active Rheumatoid Arthritis", OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, (20050000), vol. 860, page S341;, XP003032171

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 35p